Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks


From Biomarkers to Clinical Diagnostics

Omics-based biomarkers are hailed as the “holy grail” of personalized medicine and are thus considered to be of potential huge value. Their resulting wide-spread applications hold many promises, yet many hurdles still need to be overcome on the path towards a successful translation into the clinic for precise diagnosis and resulting treatment decisions in disease areas including cancer. This session will address the many aspects and learnings associated with biomarker identification, translation into clinical value, and regulatory approval for clinical use.


Andreas Kogelnik, M.D., Ph.D., Founder & Director, Open Medicine Institute (OMI)

Andreas Kogelnik, MD, PhD is founder and Director of OMI and a practicing physician. Prior to OMI, Dr. Kogelnik founded two companies and a non-profit organization. Read Full Bio

Anne D. Barker, Co-Director, Complex Adaptive Systems/ Director, National Biomarker Development Alliance (NBDA)/ Professor, School of Life Sciences Arizona State University

Dr. Barker creates transformative knowledge networks such as the NBDA, whose mission is to create standards-based end-to-end systems for biomarker discovery and development. Read Full Bio

Timothy Triche, M.D., Ph.D., Professor of Pathology, Children's Hospital Los Angeles & USC

Dr. Triche is the founder of the Center for Personalized Medicine and former Chair of the Pathology Department at Children's Hospital Los Angeles. Read Full Bio

Web Analytics